International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

Matías Maskin, MD

CEMIC University, at Buenos Aires

Buenos Aires, Argentina

Bio

PUBLICATION

Efficacy and Safety of Oral Roflumilast for Moderate-to-Severe Psoriasis—A Randomized Controlled Trial (PSORRO). Gyldenløve M, Meteran H, Sørensen J, et al. The Lancet Regional Health – Europe. 2023 Apr 21; 100639 Published Online XXX https://doi.org/10. 1016/j.lanepe.2023. 100639.

Why this article was chosen

Even though several systemic treatments are approved for psoriasis, there are just a few available oral alternatives. Biologics have high costs and are administered by injection, which might be burdensome and generate anxiety in patients. Roflumilast is already approved as a topical formulation. Still, while oral roflumilast is approved for severe COPD, this may also be a novel, cost-saving option for moderate to severe psoriasis.

Commentary

Roflumilast is a targeted phosphodiesterase (PDE)-4 inhibitor that reduces pro-inflammatory cytokines. Oral roflumilast was approved for treating severe COPD over a decade ago, and generic, low-cost versions are available in many countries. The present study evaluates the efficacy and safety of oral roflumilast in treating patients with moderate to severe plaque psoriasis. It is a company-independent, multicenter, randomized, double-blind, placebo-controlled trial conducted at three major Danish university hospitals between January 1, 2021, and December 12, 2022. Patients included had to be ≥18 years old, had chronic stable plaque psoriasis, PASI ≥8, a body mass index (BMI) ≥20 kg/m2, and should have an indication for systemic treatment. Concomitant topical treatments were not allowed except in case of significant flare-ups, where topical steroids or calcineurin inhibitors could be prescribed.

After randomization, patients were assigned by site investigators to monotherapy with either placebo or oral roflumilast 500 μg once daily for 12 weeks. All patients received open-label treatment from week 12 to 24 with oral roflumilast 500 μg once daily. The study enrolled 46 patients, of which 42 patients completed week 12 and 38 patients the week 24 visit. In roflumilast and placebo groups, the median PASI at randomization was 10.9 and 10.6.

At week 12, the efficacy primary endpoint evaluation, PASI75 was achieved by 8 (35%) patients in the roflumilast group compared to 0 (0%) patients in the placebo group (p = 0.014), and PASI50 was achieved by 70% of patients in the roflumilast group vs 4% in the placebo. During the open-label period (weeks 12 to 24), PASI75 and PASI50 were achieved in 39% and 57% of patients initially assigned to a placebo. In patients assigned to roflumilast from week 0, 44% and 65% achieved PASI75 and PASI50, respectively, and 22% achieved PASI90. There were no serious adverse events in either group or significant biochemical changes during the trial period. The most common side effects were gastrointestinal symptoms, like diarrhea, náusea, and abdominal pain.

Psoriasis has many treatment options today, but innovative oral medications with low costs are still lacking. Methotrexate is usually the only option for systemic treatment in low-income countries, despite the low rate of PASI75 responses, contraindications, and frequent side effects. Although this was not a head-to-head study, roflumilast appears to have a similar or better efficacy profile than apremilast, another approved PDE4 inhibitor. About 30% of patients reach PASI75 responses on apremilast, and gastrointestinal symptoms may be encountered more frequently.

The present study is interesting since it raises the following considerations:

  1. Oral roflumilast might help treat psoriasis and comorbidities such as COPD, obesity, and type 2 diabetes.
  2. The drug appears to be a safe and inexpensive oral option that could be used in combination with other drugs.

The study’s main limitation is that this was a small phase 2 study, with an overrepresentation of male patients. The study was only 24 weeks, so longer-term outcomes with oral roflumilast are still unclear. Nevertheless, since the drug has been approved for COPD for over a decade, extensive safety data are available from non-psoriasis populations. With the convenience of once-daily oral treatment, roflumilast may be an inexpensive alternative to other systemic treatments in patients lacking access to effective psoriasis therapies.

3 thoughts on “Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

  1. Lars Werner says:

    From a patient perspective complete clearance is the ultimate goal. In an era where we are close to PASI100 response with some MoA’s it seems like a step back and lowering the ambition level with PASI75 as the primary end point.

  2. If you didn’t have to consider costs, what would be your first choice to treat a person with mild to moderate psoriasis?
    If a patient has been in MTX with gastrointestinal side effects, would you start treatment with another medication With gastrointestinal side effects? Thank you!

  3. Carl Stewart says:

    I just finished reading the commentary on the efficacy and safety of oral roflumilast for psoriasis at psoriasiscouncil.org, and it’s a compelling analysis. The detailed exploration of the clinical data and the consideration of both efficacy and safety aspects provide a well-rounded perspective on the topic. It’s evident that the authors have a deep understanding of the subject matter, making this commentary a valuable resource for anyone interested in the latest developments in psoriasis treatment. Kudos to the Psoriasis Council for delivering such an informative and insightful piece!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Improving Medical Adherence in Psoriasis Treatments

Shining a Spotlight: Catching up with 2018 IPC Fellow Filip Rob, MD, PhD

Also Read

genetic insights

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving understanding of psoriasis management, genetic insights, and treatment strategies presented in the Gunnar Lomholt Symposium. Access the full report on the IPC website and published in JID Innovations.

Read More
health care innovation

Improving Medical Adherence in Psoriasis Treatments

Learn from Dr. Steven Feldman, a renowned expert in psoriasis treatment, about the importance of patient adherence. Discover practical strategies to enhance medication compliance and improve treatment outcomes.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.